SMS Pharmaceuticals Limited — Results, 30-05-2025: Integrated Filing- Financial

SMS Pharmaceuticals has announced a board meeting on May 30, 2025.

1) Revenue Performance: Consolidated total revenue rose to Rs. 782.75 Cr, up 10.4% YoY from Rs. 709.26 Cr, driven by strong demand in their core API and intermediates business.

2) Profitability and EPS: Net profit jumped 38.7% to Rs. 69.14 Cr from Rs. 49.83 Cr, with EPS rising from Rs. 5.89 to Rs. 8.16. Margin expansion was aided by cost control and steady volumes.

3) Operational Costs: Expenses increased to Rs. 696.63 Cr mainly due to higher raw material costs (Rs. 501.87 Cr vs. Rs. 425.26 Cr) and employee expenses (Rs. 80.08 Cr vs. Rs. 64.15 Cr), reflecting expansion efforts. Finance costs declined, supporting profits.

4) Key Metrics: EBITDA estimated at Rs. 82 Cr+, showing margin improvement. Associate profits contributed Rs. 1.74 Cr.

5) Balance Sheet / Cash Flow Health: Net debt rose slightly to Rs. 31.07 Cr to support ongoing capex, while investments in property, plant & equipment increased to Rs. 530.85 Cr, signaling capacity expansion. Cash balances improved modestly to Rs. 41.40 Cr.

6) Management Strategy: Plans include investing up to Rs. 10 Cr in subsidiary SMS Peptides Pvt Ltd and forming a new wholly-owned unit focused on greenfield pharma production in new therapy areas, highlighting diversification ambitions.

7) Final Takeaway: Robust revenue and profit growth combined with aggressive capex and margin gains position SMS Pharma well for medium-term expansion. Retail investors should monitor the contribution from new subsidiaries and capacity ramp-up. A proposed dividend of Re. 0.40 per share adds to appeal.